Clinical Research in Cardiology

, Volume 107, Issue 7, pp 539–547 | Cite as

Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design

The ASAF trial: ablation of sympathetic atrial fibrillation
  • Mark R. de Jong
  • Annemiek F. Hoogerwaard
  • Ahmet Adiyaman
  • Jaap Jan J. Smit
  • Anand R. Ramdat Misier
  • Jan-Evert Heeg
  • Boudewijn A. A. M. van Hasselt
  • Isabelle C. Van Gelder
  • Harry J. G. M. Crijns
  • Ignacio Fernández Lozano
  • Jorge E. Toquero Ramos
  • F. Javier Alzueta
  • Borja Ibañez
  • José M. Rubio
  • Fernando Arribas
  • José M. Porres Aracama
  • Josep Brugada
  • Lluís Mont
  • Arif Elvan
Original Paper

Abstract

Background

Hypertension is an important, modifiable risk factor for the development of atrial fibrillation (AF). Even after pulmonary vein isolation (PVI), 20–40% experience recurrent AF. Animal studies have shown that renal denervation (RDN) reduces AF inducibility. One clinical study with important limitations suggested that RDN additional to PVI could reduce recurrent AF.

Objective

The goal of this multicenter randomized controlled study is to investigate whether RDN added to PVI reduces AF recurrence.

Methods

The main end point is the time until first AF recurrence according to EHRA guidelines after a blanking period of 3 months. Assuming a 12-month accrual period and 12 months of follow-up, a power of 0.80, a two-sided alpha of 0.05 and an expected drop-out of 10% per group, 69 patients per group are required. We plan to randomize a total of 138 hypertensive patients with AF and signs of sympathetic overdrive in a 1:1 fashion. Patients should use at least two antihypertensive drugs. Sympathetic overdrive includes obesity, exercise-induced excessive blood pressure (BP) increase, significant white coat hypertension, hospital admission or fever induced AF, tachycardia induced AF and diabetes mellitus. The interventional group will undergo PVI + RDN and the control group will undergo PVI.

Results

Patients will have follow-up for 1 year, and continuous loop monitoring is advocated.

Conclusion

This randomized, controlled study will elucidate if RDN on top of PVI reduces AF recurrence.

Keywords

RDN PVI AF Hypertension Sympathetic overdrive 

Notes

Compliance with ethical standards

Conflict of interest

The study receives sponsoring from the Medtronic External Research Program. Dr. J. Toquero Ramos reports his membership of the Medtronic European Advisory Board. The other authors declare no conflict of interest.

References

  1. 1.
    Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GYH, Dorian P, Shestakovska O, Connolly SJ (2013) The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 34:170–176CrossRefPubMedGoogle Scholar
  2. 2.
    Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. New Engl J Med 361:932–934CrossRefPubMedGoogle Scholar
  3. 3.
    Steigerwald K, Titova A, Malle C, Kennerknecht E, Jilek C, Hausleiter J, Nährig JM, Laugwitz KL, Joner M (2012) Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens 30:2230–2239CrossRefPubMedGoogle Scholar
  4. 4.
    Zhao Q, Yu S, Zou M, Dai Z, Wang X, Xiao J, Huang C (2012) Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. J Interv Card Electrophysiol 35:119–125CrossRefPubMedGoogle Scholar
  5. 5.
    Esler MD, Krum H, Sobotka P, Schlaich MP, Schmieder RE, Böhm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903–1909CrossRefPubMedGoogle Scholar
  6. 6.
    Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C (2012) ESH position paper: renal denervation—an interventional therapy of resistant hypertension. J Hypertens 30:837–841CrossRefPubMedGoogle Scholar
  7. 7.
    Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC (2012) Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 60:1956–1965CrossRefPubMedGoogle Scholar
  8. 8.
    Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP (2012) Renal denervation in moderate to severe CKD. J Am Soc Nephrol 23:1250–1257CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281CrossRefPubMedGoogle Scholar
  10. 10.
    Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, Reddy VY (2012) Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 5:758–765CrossRefPubMedGoogle Scholar
  11. 11.
    Kaltenbach B, Franke J, Bertog SC, Steinberg DH, Hofmann I, Sievert H (2013) Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study. Catheter Cardiovasc Interv 81:335–339CrossRefPubMedGoogle Scholar
  12. 12.
    Symplicity HTN-1 investigators (2011) Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57:911–917CrossRefGoogle Scholar
  13. 13.
    Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, Brandt MC, Hoppe UC, Krum H, Esler M, Sobotka PA, Böhm M (2011) Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 58:1176–1182CrossRefPubMedGoogle Scholar
  14. 14.
    Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59:901–909CrossRefPubMedGoogle Scholar
  15. 15.
    Liang Z, Shi XM, Liu LF, Chen XP, Shan ZL, Lin K, Li J, Chen FK, Li YG, Guo HY, Wang YT (2015) Renal denervation suppresses atrial fibrillation in a model of renal impairment. PLoS One 10:e0124123CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yamada S, Lo LW, Chou YH, Lin WL, Chang SL, Lin YJ, Chen SA (2017) Renal denervation regulates the atrial arrhythmogenic substrates through reverse structural remodeling in heart failure rabbit model. Int J Cardiol 235:105–113CrossRefPubMedGoogle Scholar
  17. 17.
    Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS (2012) A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 60:1163–1170CrossRefPubMedGoogle Scholar
  18. 18.
    Romanov A, Pokushalov E, Ponomarev D et al (2017) Pulmonary vein isolation with concomitantrenal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: data from implantable cardiac monitor. Cardiovasc Ther 35:e12264.  https://doi.org/10.1111/1755-5922.12264 CrossRefGoogle Scholar
  19. 19.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F (2014) Task force for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 23:3–16CrossRefPubMedGoogle Scholar
  20. 20.
    Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA (2002) Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol 40:126–132CrossRefPubMedGoogle Scholar
  21. 21.
    Gal P, de Jong MR, Smit JJJ, Adiyaman A, Staessen JA, Elvan A (2015) Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J Hum Hypertens 29:292–295CrossRefPubMedGoogle Scholar
  22. 22.
    De Jong MR, Adiyaman A, Gal P, Smit JJ, Delnoy PP, Heeg JE, van Hasselt BA, Lau EO, Persu A, Staessen JA, Ramdat Misier AR, Steinberg JS, Elvan A (2016) Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension 68:707 – 14CrossRefPubMedGoogle Scholar
  23. 23.
    De Jong MR, Hoogerwaard AF, Gal P, Adiyaman A, Smit JJ, Delnoy PP, Ramdat Misier AR, van Hasselt BA, Heeg JE, le Polain de Waroux JB, Lau EO, Staessen JA, Persu A, Elvan A (2016) Persistent increase in blood pressure after renal nerve stimulation in accessory renal arteries after sympathetic renal denervation. Hypertension 67:1211–1217CrossRefPubMedGoogle Scholar
  24. 24.
    Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger RH, Wirth K, Böhm M (2012) Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 60:172–178CrossRefPubMedGoogle Scholar
  25. 25.
    Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Böhm M (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60:419–424CrossRefPubMedGoogle Scholar
  26. 26.
    Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M, Schmieder RE (2012) Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens 14:799–801CrossRefGoogle Scholar
  27. 27.
    Staessen J, Jin Y, Thijs L, Persu A, Azizi M, Kjeldsen S (2013) First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern. J Am Coll Cardiol 62:445–446CrossRefGoogle Scholar
  28. 28.
    Ziegler AK, Franke J, Bertog SC (2013) Renal denervation in a patient with prior renal artery stenting. Catheter Cardiovasc Interv 81:342–345CrossRefPubMedGoogle Scholar
  29. 29.
    Vonend O, Antoch G, Rump LC, Blondin D (2012) Secondary rise in blood pressure after renal denervation. Lancet 380:778CrossRefPubMedGoogle Scholar
  30. 30.
    Tsioufis C, Papademetriou V, Tsiachris D, Dimitriadis K, Kasiakogias A, Kordalis A, Antonakis V, Kefala A, Thomopoulos C, Kallikazaros I, Lau EO, Stefanadis C (2014) Drug-resistant hypertensive patients responding to multielectrode renal denervation exhibit improved heart rate dynamics and reduced arrhythmia burden. J Hum Hypertens 28:587 – 93CrossRefPubMedGoogle Scholar
  31. 31.
    Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O’Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators (2014) Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol 64:1071–1078CrossRefPubMedGoogle Scholar
  32. 32.
    Elvan A, Adiyaman A, Beukema RJ, Sie HT, Allessie MA (2013) Electrophysiological effects of acute atrial stretch on persistent atrial fibrillation in patients undergoing open heart surgery. Heart Rhythm 10:322 – 30CrossRefPubMedGoogle Scholar
  33. 33.
    Qiu M, Yuehui Y, Shan Q (2013) Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial. Trials 14:168. http://www.trialsjournal.com/content/14/1/168. Accessed 22 Feb 2018
  34. 34.
    Renal nerve denervation in patients with hypertension and paroxysmal and persistent atrial fibrillation (symplicity AF). NCT02064764. https://clinicaltrials.gov/ct2/show/NCT02064764
  35. 35.
    Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G, Renal Denervation for Hypertension (DENERHTN) investigators (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385:1957–1965CrossRefPubMedGoogle Scholar
  36. 36.
    Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M, SPYRAL HTN-OFF MED trial investigators (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390:2160–2170CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Mark R. de Jong
    • 1
  • Annemiek F. Hoogerwaard
    • 1
  • Ahmet Adiyaman
    • 1
  • Jaap Jan J. Smit
    • 1
  • Anand R. Ramdat Misier
    • 1
  • Jan-Evert Heeg
    • 2
  • Boudewijn A. A. M. van Hasselt
    • 3
  • Isabelle C. Van Gelder
    • 4
  • Harry J. G. M. Crijns
    • 5
  • Ignacio Fernández Lozano
    • 6
  • Jorge E. Toquero Ramos
    • 6
  • F. Javier Alzueta
    • 7
  • Borja Ibañez
    • 8
  • José M. Rubio
    • 8
  • Fernando Arribas
    • 9
  • José M. Porres Aracama
    • 10
  • Josep Brugada
    • 11
  • Lluís Mont
    • 11
  • Arif Elvan
    • 1
  1. 1.Department of CardiologyIsala HospitalZwolleThe Netherlands
  2. 2.Department of Internal MedicineIsala HospitalZwolleThe Netherlands
  3. 3.Department of RadiologyIsala HospitalZwolleThe Netherlands
  4. 4.Department of CardiologyUniversity of GroningenGroningenThe Netherlands
  5. 5.Department of CardiologyMaastricht Universitair Medisch CentrumMaastrichtThe Netherlands
  6. 6.Department of Arrhythmia UnitHospital Universitario Puerta de HierroMadridSpain
  7. 7.Department of Arrhythmia UnitHospital Universitario Virgen de la VictoriaMálagaSpain
  8. 8.Department of CardiologyHospital Fundación Jimenez DíazMadridSpain
  9. 9.Department of CardiologyHospital Universitario 12 de OctubreMadridSpain
  10. 10.Department of CardiologyHospital DonostiaSan SebastianSpain
  11. 11.Arrhythmia Unit, Cardiovascular Institute, Hospital ClínicUniversity of BarcelonaBarcelonaSpain

Personalised recommendations